10X Genomics Inc (TXG)
10x Genomics, Inc. is a healthcare company focused on life sciences tools and services, with common stock listed on NASDAQ under the ticker TXG. The company develops and sells instruments, consumables, and software used to study biological systems across the United States and international markets including the Americas, Europe, the Middle East and Africa, China, and the Asia Pacific region. Its product portfolio includes the Chromium platform for single-cell analysis, along with related microfluidic chips, consumables, and Chromium instruments. It also provides the Chromium X Series and QuantumScale kits for single-cell RNA and methylation analysis. In spatial biology, the company offers the Visium platform and Visium CytAssist instrument, and it also markets the Xenium Analyzer for in situ RNA detection, together with slides and reagents. Software products include Cell Ranger, Loupe Browser, and Xenium Explorer. 10x Genomics serves academic, government, biopharmaceutical, biotechnology, and other research institutions.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TXG
|
$40.92
|
-42.8% Downside
|
Overvalued
|
$77.50
|
8.3% Upside
|
Fair
|
Good
|
0.0%
|
November 5, 2026
|
11.3x
|
15.1x
|
9.322 B
|
8.849 B
|
0.8%
|
90.7%
|
26.1
|
-161.6%
|
